idea-014 · desirability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the child (ages 5-17) with physician-diagnosed persistent asthma, the parent/guardian who has to make the daily routine happen, and the prescribing clinician (pediatrician, pediatric pulmonologist, or allergist) who has to order it.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-014.md — the number is the claim's position in its ## Claims list, the tag is copied from it and never adjusted here. A [no claim] marker means nothing in the file speaks to the condition at all. See docs/deck-spec.md.
First build. This candidate cleared the Stage 5 gate at 6/9 factors verified, but the rubric scores no factor for whether a user wants this — the gap the deck spec names as the single most useful thing this artifact produces. Two of this deck's own conditions had no claim behind them at all before this build and are now write-backs (claims 26-27).
Would have to be true: A substantial population of children ages 5-17 with physician-diagnosed persistent (not merely intermittent) asthma would have to experience symptoms or attacks frequently enough, between clinic visits, that continuous home monitoring changes what happens to them versus periodic in-office spirometry and action-plan review.
Where it stands: The population figure in the file is all-severity, not persistent-only: approximately 4.8 million US children under 18 had "current asthma" in 2023 (6.7% of the child population), with about 2.3 million of those (47.1%) reporting an asthma attack in the prior year [claim 7: unconfirmed] — web-search sourced, no primary CDC/NHIS table attached. The persistent-vs-intermittent split is on firmer footing but from an older dataset: an estimated 60.3% of US children with current asthma have persistent-severity asthma versus 39.7% intermittent, per CDC's BRFSS Adult Asthma Call-back Survey (35 states + DC, 2006-2010) [claim 22: verified]. The two figures are not from the same year or the same survey instrument, so multiplying them is not itself a verified number — see the viability deck's Slide 3 for that decomposition, referenced rather than repeated here.
What would settle it: A primary CDC/NHIS table breaking out persistent-vs-intermittent pediatric asthma prevalence for a recent year, matching claim 7's 2023 vintage rather than claim 22's 2006-2010 vintage.
If it's false: There is no addressable population experiencing the between-visit symptom burden this device is built to catch, and the viability deck's TAM slide fails on the same unresolved population leg.
Would have to be true: A parent/guardian and the child together would have to perform a daily home peak-flow/spirometry maneuver and complete a symptom-and-medication-adherence questionnaire, with enough consistency to produce clinically useful data — RPM billing under CPT 99454 specifically requires at least 16 days of readings in a 30-day period — rather than relying on periodic in-office spirometry as they do today.
Where it stands: This is the candidate's own explicitly flagged design assumption, now carried as a formal claim: parents/guardians and school-age children being willing to perform this daily maneuver and questionnaire with enough consistency for the 16-of-30-day RPM threshold [claim 14: unconfirmed]. The file states plainly that "no primary adherence data for this population and device concept is cited here" and that no connector in this repo reaches stakeholder-preference questions.
What would settle it: A small adherence pilot with the actual target population (ages 5-17, persistent asthma), measuring the fraction of enrolled families who sustain 16+ days of readings per 30-day period.
If it's false: The device never generates enough data to bill CPT 99454 in the first place — a desirability failure that is simultaneously a viability failure (see the viability deck's Slide 2, which references this condition rather than restating it).
Would have to be true: The prescribing clinician would have to be willing to order home RPM monitoring for persistent pediatric asthma and bill the associated CPT codes, rather than treating in-office spirometry and periodic action-plan review as sufficient — and that clinician's payer would have to agree the device and indication actually qualify for RPM billing in the first place.
Where it stands: The clinician-willingness half is the file's own stated assumption: prescribing physicians (pediatricians, pediatric pulmonologists, allergists) being willing to order this monitoring and bill for it "at a rate sufficient to justify a dedicated device, rather than treating in-office spirometry and periodic action-plan review as sufficient" [claim 13: unconfirmed]. The payer-eligibility half is a viability-lens question this deck defers to rather than duplicates: whether this device/indication actually satisfies CMS's general RPM eligibility criteria "in a way that a general-wellness OTC peak-flow app would not" remains an unsourced design assumption [claim 11: unconfirmed] — see the viability deck's Slide 1 for the sharper version of this question (which payer, at what rate).
What would settle it: Structured interviews with pediatric prescribers on ordering and billing willingness for this specific indication; the payer question is settled where the viability deck names it.
If it's false: The consent chain breaks at the point of prescription even if the family would want the device — nobody writes the order, and there is no patient to observe adherence in at all.
Would have to be true: The daily burden of the maneuver and questionnaire, plus whatever the family pays out of pocket after insurance reimburses the RPM charges, would have to be worth it relative to the symptom and cost burden the family already carries.
Where it stands: The baseline cost burden the family is already carrying is verified: children and adolescents with treated asthma incur $3,362.56 in additional annual medical expenditures compared with those without treated asthma, per a 2016-2021 Medical Expenditure Panel Survey analysis of 2,365 treated-asthma children versus 40,497 without [claim 25: verified]. What the family would additionally pay out of pocket for this device and program is not in the file at all — no copay, coinsurance percentage, or cash-pay figure appears anywhere. Formalized in this deck's write-back rather than left silent: families would have to be able and willing to pay whatever out-of-pocket cost remains after insurance reimburses the CPT 99453/99454/99457 charges [claim 26: unverified]. The dollar figures behind that reimbursement — and the sharper question of which payer even pays them for a pediatric patient — are the viability deck's Slide 1, referenced rather than restated here.
What would settle it: A stated coinsurance or cash-pay figure for RPM services under a pediatric-covering payer, which no claim in the file currently supplies; family willingness- to-pay research at that price point once it exists.
If it's false: A family that finds the daily routine burdensome and the added out-of-pocket cost not worth it reverts to periodic in-office spirometry, and the RPM data stream this device depends on for both billing and clinical value stops.
Would have to be true: Parents and prescribers would need to see this specific program actually reduce exacerbations, ED visits, or hospitalizations early enough to keep using it — not merely see a device that measures accurately.
Where it stands: The only clinical evidence in the file speaks to measurement accuracy, not outcomes, and it is about a different product: an app-based portable home spirometer (VitalFlo) correlated highly with a clinic-grade spirometer in 48 adolescents with persistent asthma (240 measurements), no statistically significant difference in mean FEV1 (P=.87) [claim 24: verified]. No claim in the file shows that a home RPM program of this kind reduces exacerbations, ED visits, or hospitalizations — an outcome question distinct from instrument accuracy. Formalized in this deck's write-back: enrolling a pediatric persistent-asthma patient in this program reduces exacerbations, ED visits, or hospitalizations relative to standard in-office spirometry and periodic action-plan review [claim 27: unverified]. Two adjacent attempts to run something like this never reached completion: a Philips-sponsored pediatric home-asthma-RPM study (ALPACA, ages 4-11, moderate-to-severe asthma) was withdrawn before enrolling any participants, reason "refocus of business" [claim 19: verified]; a Weill Cornell pilot of remote asthma-medication monitoring (ages 3-21, persistent asthma) was terminated after enrolling 12 participants, reason "Staffing issues with partner site" [claim 20: verified]. Both stopped for operational reasons, not for a finding against efficacy — but neither produced the outcome evidence this slide is asking for either.
What would settle it: An outcomes study (exacerbation, ED-visit, or hospitalization rate) comparing enrolled patients to a standard-of-care comparator — the nearest two attempts at this never reached that stage.
If it's false: The device becomes a compliance-and-billing exercise for the clinician without a belief-forming result for the family, and adherence (Slide 2) has no reason to outlast the novelty period.
Would have to be true: A small number of structured conversations with pediatric prescribers and families of children with persistent asthma would have to return a consistent signal on three questions at once: would a prescriber order and bill it, would a family sustain the 16-of-30-day adherence threshold, and would the out-of-pocket cost be tolerable.
Where it stands: No primary research of any kind exists in the file on any of these three questions — no connector in this repo reaches clinician- or family-preference data, and the file says so explicitly for claims 13 and 14. The three conditions this conversation would test are now individually on record as claims 13, 14, and 26 (the last two unconfirmed/ unverified), rather than living only as prose in this deck.
What would settle it: Prescriber and family interviews, or a small willingness/ acceptability study — the single highest-yield unspent step, since it resolves Slides 2, 3, and 4 in the same conversation.
If it's false: The idea remains a billing-eligibility argument (see the indication-scope note in the candidate file) built without ever asking the people who would have to use it daily whether they will.
Every condition above with nothing verified behind it — the [no claim] markers, plus the unverified claims this deck itself put on record. Read this slide first.
Structural note: the only verified claims this deck can lean on are a persistent-asthma severity split from a 2006-2010 dataset (claim 22), a baseline cost-burden figure (claim 25), an accuracy study of a different product (claim 24), and two trials that never enrolled or completed (claims 19-20). Consistent with the rubric's own gap, nothing scores desirability directly — this deck's reliance on unconfirmed and freshly unverified write-backs is what that gap looks like on this candidate.
If only one thing from this chair could be checked: whether parents/guardians and school-age children with persistent asthma will actually sustain at least 16 days of home peak-flow/spirometry readings and questionnaire responses in a 30-day period [claim 14: unconfirmed].
Every other slide on this deck sits downstream of it. If daily adherence does not hold, there is no valid RPM data stream regardless of whether a prescriber orders the device (Slide 3), no CPT 99454 billing eligibility regardless of what a payer would pay (viability deck Slide 2), and no outcome evidence to ever generate (Slide 5) — the file's own design-rationale note carries this as an assumption, not a fact, and it is the one number in it that is already quantified (16 of 30 days) and therefore the cheapest to actually go test.
Naming it is not a recommendation, a gate, or a kill. It is the answer to "check what first."